Abstract 2891: Bench-to-bedside development of a novel idiotype vaccine against lymphoma
Hong Qin(The University of Texas MD Anderson Cancer Center), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Sheeba K. Thomas(The University of Texas MD Anderson Cancer Center), Dongho Gwak(The University of Texas MD Anderson Cancer Center), Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Soung-chul Cha(The University of Texas MD Anderson Cancer Center), Sung-Doo Kim(The University of Texas MD Anderson Cancer Center), Sheetal Rao(The University of Texas MD Anderson Cancer Center), Sapna Parshottam(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
|Nature Medicine|2024|452
Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience
|British Journal of Haematology|2014|364
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
|The Lancet Oncology|2014|263
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation
|Journal of Clinical Oncology|2016|187